



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Welcome to DialogClassic Web(tm)

Dialog level 05.01.00D

Last logoff: 26apr05 15:19:27

Logon file001 28apr05 11:55:10

*** ANNOUNCEMENT ***

--Important Notice to Freelance Authors--

See HELP FREELANCE for more information

NEW FILES RELEASED

***FDAnews (File 182)

***German Patents Fulltext (File 324)

***Beilstein Abstracts (File 393)

***Beilstein Facts (File 390)

***Beilstein Reactions (File 391)

RELOADED

***Medline (Files 154 & 155)

***ToxFile (File 156)

RESUMED UPDATING

***Canadian Business and Current Affairs (262)

***CorpTech (559)

REMOVED

***Health News Daily (43)

***FDC Reports Gold Sheet/Silver Sheet (184)

***FDC Reports (186/187)

***NDA Pipeline: New Drugs (189)

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HIGHLIGHT set on as ' '

* * *

File 1:ERIC 1966-2004/Jul 21

(c) format only 2004 The Dialog Corporation

*File 1: Updates suspended by ERIC until
Q2, 2005

Set Items Description

--- --

Cost is in DialUnits

?

B 155, 5, 73

28apr05 11:55:30 User259876 Session D746.1

\$0.79 0.227 DialUnits File1

\$0.79 Estimated cost File1

\$0.08 INTERNET

\$0.87 Estimated cost this search

\$0.87 Estimated total session cost 0.227 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1951-2005/Apr W4

(c) format only 2005 The Dialog Corp.

File 5:Biosis Previews(R) 1969-2005/Apr W3

growth factors. However, little is known regarding the regulation of their expression and composition under pathophysiological conditions. In the present study, we have investigated...

...key heparan sulfate chain-carrying core proteins, syndecan-1 and syndecan-4, in a mouse/rat infarct model of tissue injury and repair. Induction of **myocardial** infarction was associated with a prompt increase in expression of both syndecan genes. Although infiltrating macrophages accounted for a substantial increase in syndecan expression, increased expression was noted in the levels of syndecan-1 mRNA in endothelial cells and syndecan-4 mRNA in **cardiac** myocytes. This increase in expression was limited to the immediate peri- infarct region and was absent from remote areas of the left or right ventricles. The influx of blood-derived macrophages in the **heart** correlated with the appearance of PR-39 peptide, which has previously been shown to increase syndecan expression in vitro. Studies in the op/op mice strain (which demonstrates sharply reduced levels of circulating monocytes) showed that **myocardial** infarction was associated with markedly reduced levels of macrophage influx and corresponding reduction in the expression of PR-39 and both syndecan genes. Pretreatment of op/op mice with granulocyte macrophage **colony - stimulating factor** restored **myocardial** macrophage content with corresponding restoration of PR-39/syndecan expression. In summary, **myocardial** infarction is associated with a distinct spatial and temporal pattern of syndecan-1 and -4 gene expression, which is induced by an influx of blood...

MEDICAL DESCRIPTORS:

* **heart** infarction

angiogenesis ; animal model; article; extracellular matrix; gene expression; macrophage; mouse; nonhuman; priority journal; rat; wound healing

?

Set	Items	Description
S1	2350173	(CARDIAC OR HEART OR MYOCARDIAL OR CARDIOMYOPATHY)
S2	6359	S1 AND (ANGIOGENESIS OR NEOVASCULARIZATION)
S3	29	S2 AND (SCF OR SLF OR (STEEL (W) FACTOR) OR (STEM (W) CELL (W) FACTOR))
S4	26	RD (unique items)
S5	107	S2 AND (CSF OR (COLONY (W) STIMULATING (W) FACTOR))
S6	96	RD (unique items)
S7	110	S4 OR S6
S8	19	S7 AND (EPC OR (ENDOTHELIAL (W) PROGENITOR?))
S9	19	RD (unique items)
S10	0	S9 NOT PY>1999
S11	11223	(VECTOR OR DNA) (S) ((ANGIOGENIC (W) PROTEIN) OR VEGF OR HGF OR ?FGF OR EGF)
S12	4	S7 AND S11
S13	4	RD (unique items)
S14	31	S7 AND (MOBILIZATION)
S15	21	S14 NOT (S13 OR S9)
S16	3	S7 AND (ANTI-COAGULANT OR UROKINASE OR HEPARIN OR (PLASMIN- OGEN (W) ACTIVATOR))

?

COST

28apr05 12:18:06 User259876 Session D746.2
 \$5.93 1.854 DialUnits File155
 \$1.89 9 Type(s) in Format 3
 \$1.89 9 Types

\$7.82 Estimated cost File155
\$11.08 1.927 DialUnits File5
\$20.00 10 Type(s) in Format 3
\$20.00 10 Types
\$31.08 Estimated cost File5
\$20.72 1.949 DialUnits File73
\$82.32 28 Type(s) in Format 3
\$82.32 28 Types
\$103.04 Estimated cost File73
OneSearch, 3 files, 5.730 DialUnits FileOS
\$6.13 INTERNET
\$148.07 Estimated cost this search
\$148.94 Estimated total session cost 5.957 DialUnits

?

Return to logon page!



Refine Search

Search Results -

Term	Documents
(18 NOT 16).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	62
(L18 NOT L16).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	62

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L19

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Thursday, April 28, 2005 [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND			
<u>L19</u>	L18 not L16	62	<u>L19</u>
<u>L18</u>	L17 and (EPC or (endothelial adj progenitor))	111	<u>L18</u>
<u>L17</u>	L7 or L8	3118	<u>L17</u>
<u>L16</u>	L15 not L13	49	<u>L16</u>
<u>L15</u>	L14 and (EPC or (endothelial adj progenitor))	77	<u>L15</u>
<u>L14</u>	L10 or L11	1219	<u>L14</u>
<u>L13</u>	L12 and (ischemic or ischemia)	294	<u>L13</u>
<u>L12</u>	L11 and L10	355	<u>L12</u>
<u>L11</u>	L9 and L8	1193	<u>L11</u>
<u>L10</u>	L9 and L7	381	<u>L10</u>

(vector or DNA or (nucleic adj acid)) same ((angiogenic adj protein) or

<u>L9</u>	VEGF or aFGF or bFGF or EGF or PDGF or HGF)	8133	<u>L9</u>
<u>L8</u>	L6 and (CSF)	3058	<u>L8</u>
<u>L7</u>	L6 and (SCF or SLF or (Steel adj factor))	693	<u>L7</u>
<u>L6</u>	L5 and (angiogenesis or neovascularization)	13054	<u>L6</u>
<u>L5</u>	(cardiac or heart or myocardial or cardiomyopathy)	243114	<u>L5</u>
<u>L4</u>	L3 and (SCF or CSF)	12	<u>L4</u>
<u>L3</u>	L1 or L2	38	<u>L3</u>
<u>L2</u>	Isner-Jeffrey-M\$.in.	30	<u>L2</u>
<u>L1</u>	Asahara-Takayuki.in.	15	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Term	Documents
(3 AND 2).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	119
(L3 AND L2).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	119

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L5

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Friday, April 29, 2005 [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND</i>			
<u>L5</u>	L3 and L2	119	<u>L5</u>
<u>L4</u>	(echocardiography and LVEDD and LVESD and NOGA and LVSP and (cardiac adj angiography))	1	<u>L4</u>
<u>L3</u>	(echocardiography or LVEDD or LVESD or NOGA or LVSP or (cardiac adj angiography))	3266	<u>L3</u>
<u>L2</u>	L1 and (angiogenic adj (protein or factor))	901	<u>L2</u>
<u>L1</u>	(cardiomyopathy or (myocardial adj ischemia))	12123	<u>L1</u>

END OF SEARCH HISTORY